Psyence Biomedical Ltd.
PBM evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for PBM—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · PBM
Psyence Biomedical Ltd. is a clinical-stage biotechnology company focused on developing psychedelic-based therapeutics, currently conducting a Phase IIb clinical trial in Australia and facing significant capital requirements to fund ongoing operations and regulatory pathways.
Key risk: Going concern uncertainty
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Financial data as of Sep 30, 2025.
Psyence Biomedical Ltd. is a clinical-stage biotechnology company focused on developing psychedelic-based therapeutics, currently conducting a Phase IIb clinical trial in Australia and facing significant capital requirements to fund ongoing operations and regulatory pathways.
- Cash and equivalents of $7.1M as of 2025-09-30 [sec].
- Net income of -$0.8M for the period ended 2025-09-30 [sec].
- Shareholders' equity of -$11.0M as of 2025-09-30 [sec].
- Conducting a Phase IIb clinical trial in Australia through its subsidiary and contract research organization [sec · filed 2026-06-22].
- The company has transitioned from PEX010 to PsyLabs' NPX-5 as the product candidate for its Phase IIb study [sec · filed 2026-06-22].
What works
- As of March 31, 2026, the company had a positive working capital position of $8,487,385, an improvement from $5,965,908 a year earlier [sec · filed 2026-06-22].
- The company has secured financing through shareholder investments, a loan facility against its expected Australian Tax Office R&D rebate, and the rebate itself [sec · filed 2026-06-22].
- The company is actively conducting a Phase IIb clinical trial in Australia, indicating progress in its development pipeline [sec · filed 2026-06-22].
What to weigh
- Psyence has incurred significant losses since inception and expects to continue incurring losses for the foreseeable future [sec · filed 2026-06-22].
- The company will require substantial additional funding to achieve its business goals, and its ability to continue as a going concern is uncertain [sec · filed 2026-06-22].
- Shareholders' equity is negative at -$11.0M as of 2025-09-30, reflecting accumulated losses [sec].
- The company's operating results are expected to fluctuate significantly due to factors such as delays in clinical trials and partnership agreements [sec · filed 2026-06-22].
From the filings
Quoted directly from source documents.
The company has a positive working capital position as of March 31, 2026.
“As of March 31, 2026, the Company had a cash balance of $7,491,954 and a positive working capital position of $8,487,385”
SEC filings · June 22, 2026
The company has transitioned from PEX010 to NPX-5 for its Phase IIb study.
“to terminate the Filament term sheet and transition from PEX010 to PsyLabs' NPX-5 as the product candidate used in the Company's Phase IIb Study.”
SEC filings · June 22, 2026
The company has incurred significant losses since inception.
“We are a clinical-stage biotechnology company and have incurred significant losses since our inception.”
SEC filings · June 22, 2026
The company requires substantial additional funding.
“The Company will require substantial additional funding to achieve its business goal”
SEC filings · June 22, 2026
Risks & what to watch (4)›
Key risks
- Going concern uncertainty — The company has negative shareholders' equity and expects to need additional funding to continue operations [sec · filed 2026-06-22].
- Clinical trial delays — Delays in commencement, enrollment, and timing of clinical trials could adversely affect operations [sec · filed 2026-06-22].
- Regulatory approval risk — Product candidates may fail to demonstrate effectiveness or safety, or gain regulatory approval [sec · filed 2026-06-22].
- Dependence on partnerships — Delays in finding and establishing partnerships could hinder development and commercialization [sec · filed 2026-06-22].
What to watch
- Progress and results of the Phase IIb clinical trial in Australia [sec · filed 2026-06-22].
- Any updates on FDA assessment for fast-track or breakthrough therapy designation [sec · filed 2026-06-22].
- Changes in cash position and working capital, as the company may need to raise additional funds [sec · filed 2026-06-22].
- Developments in partnership agreements or licensing arrangements, particularly with PsyLabs [sec · filed 2026-06-22].
Sources: SEC filings · Generated August 26, 2026 · How we verify sources →
Run Psyence Biomedical Ltd. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Psyence Biomedical Ltd. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
38.1 months
D/E 0.08
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
1
Total value held
$218
| Holder | Shares | Value |
|---|---|---|
| stonehage fleming financial services holdings ltd | 89 | $218 |
Short Interest
as of Apr 28, 2026- % of float
- 1.9%
- Days to cover
- 2.2
- Shares short
- 43,145
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
PBM short interestFrequently asked questions
What is the AI investment thesis for Psyence Biomedical Ltd.?
Psyence Biomedical Ltd. is a clinical-stage biotechnology company focused on developing psychedelic-based therapeutics, currently conducting a Phase IIb clinical trial in Australia and facing significant capital requirements to fund ongoing operations and regulatory pathways.
Who is the CEO of Psyence Biomedical Ltd.?
Mr. Jody Aufrichtig is the chief executive officer of Psyence Biomedical Ltd. (PBM).
Where is Psyence Biomedical Ltd. headquartered?
Psyence Biomedical Ltd. (PBM) is headquartered in Toronto, ON, Canada.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.